Welcome to Helix Talk, a podcast presented by the Rosalm Franklin University College of Pharmacy.

This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge.

This is an educational production, copyright Rosalind Franklin University of Medicine and Science.

This podcast contains general information for educational purposes only. This is not professional advice and should

not be used in lieu of obtaining advice from a qualified health care provider. And now, on to the show.

Welcome to episode six of Helix Talk. I'm your co-host,. Kane. Hi, I'm Dr. Patel. And I'm Dr.

Schumann. And today we're talking about the gold guidelines and we're going to be focusing on

kind of an overview of the treatment of COPD, but really honing in on some of the newer agents

for COPD that you may not be that familiar with. So to kick it off, I think it's important

to at least mention some of the diagnostic criteria

for COPD because I really think it helps emphasize how a patient with COPD feels in terms

of their respiratory status.

So we're considering diagnosis of COPD in any patient who complains of dyspnea, has

chronic cough or sputin production, and a history of risk

factors such as tobacco smoking, exposure to smoke from cooking or heating fuels or occupational

dust or chemicals.

Really, the gold standard once you've established a risk of COPD with symptoms is to do

spirometry. And the way that COPD is diagnosed is based on what's

called the FV1 divided by the FVC. What those mean are the forced expatory volume in one second,

so how much air you can blow out in one second, divided by your functional vital capacity,

...